Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...
The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
A diagnosis of dementia may create very mixed emotions. Coming to terms with it, making decisions and planning ahead are all part of living well with dementia. Getting information and support when you ...
The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...
NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not ...